Effetti cardiocircolatori dell'insulina nel paziente con insufficienza cardiaca.

Translated title of the contribution: Cardiocirculatory effects of insulin in patients with heart failure

Gabriele Tumminello, Marco Guazzi

Research output: Contribution to journalArticle

Abstract

Insulin is a hormone that possesses several therapeutic properties, some of which are only partially known and not definitely appreciated. Insulin appears to be an attractive therapeutic tool in several cardiovascular diseases and particularly in chronic heart failure (CHF). Insulin, in fact, exerts a direct effect on biological properties of myocytes by increasing the transmembrane glucose transport through glucose-specific insulin-regulated receptors, whose gene expression is down-regulated since the initial stages of myocyte hypertrophy. In addition, a hormonal antiapoptotic molecular effect has also been reported. These effects explain, at least in part, the observed improvement in ejection fraction and cardiac output in CHF patients when given insulin. Vasodilation is the most remarkable peripheral effect of insulin that seems to be due to a direct activity on vascular smooth muscle cells and, more remarkably, on an increased release of endothelium-derived relaxing factors, such as nitric oxide and vasodilator prostaglandins. In accordance with most recent clinical observations, this endothelial modulatory activity is not limited to the systemic circulation but involves also the pulmonary one and the alveolar-capillary interface, resulting in a facilitation of the alveolar gas diffusion. Such an effect on alveolar gas diffusion appears to play a major role in CHF patients. The present review focuses on the pathophysiological mechanisms underlying the insulin benefits, and emphasizes the hormone therapeutic applicability in a CHF setting.

Original languageItalian
Pages (from-to)368-374
Number of pages7
JournalItalian Heart Journal
Volume4
Issue number5 Suppl
Publication statusPublished - May 2003

Fingerprint

Heart Failure
Insulin
Muscle Cells
Gases
Hormones
Glucose
Endothelium-Dependent Relaxing Factors
Insulin Receptor
Vasodilator Agents
Vascular Smooth Muscle
Vasodilation
Cardiac Output
Hypertrophy
Prostaglandins
Smooth Muscle Myocytes
Nitric Oxide
Cardiovascular Diseases
Therapeutics
Gene Expression
Lung

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effetti cardiocircolatori dell'insulina nel paziente con insufficienza cardiaca. / Tumminello, Gabriele; Guazzi, Marco.

In: Italian Heart Journal, Vol. 4, No. 5 Suppl, 05.2003, p. 368-374.

Research output: Contribution to journalArticle

@article{8dd3eff4f6434884b6b1e3a8e8721259,
title = "Effetti cardiocircolatori dell'insulina nel paziente con insufficienza cardiaca.",
abstract = "Insulin is a hormone that possesses several therapeutic properties, some of which are only partially known and not definitely appreciated. Insulin appears to be an attractive therapeutic tool in several cardiovascular diseases and particularly in chronic heart failure (CHF). Insulin, in fact, exerts a direct effect on biological properties of myocytes by increasing the transmembrane glucose transport through glucose-specific insulin-regulated receptors, whose gene expression is down-regulated since the initial stages of myocyte hypertrophy. In addition, a hormonal antiapoptotic molecular effect has also been reported. These effects explain, at least in part, the observed improvement in ejection fraction and cardiac output in CHF patients when given insulin. Vasodilation is the most remarkable peripheral effect of insulin that seems to be due to a direct activity on vascular smooth muscle cells and, more remarkably, on an increased release of endothelium-derived relaxing factors, such as nitric oxide and vasodilator prostaglandins. In accordance with most recent clinical observations, this endothelial modulatory activity is not limited to the systemic circulation but involves also the pulmonary one and the alveolar-capillary interface, resulting in a facilitation of the alveolar gas diffusion. Such an effect on alveolar gas diffusion appears to play a major role in CHF patients. The present review focuses on the pathophysiological mechanisms underlying the insulin benefits, and emphasizes the hormone therapeutic applicability in a CHF setting.",
author = "Gabriele Tumminello and Marco Guazzi",
year = "2003",
month = "5",
language = "Italian",
volume = "4",
pages = "368--374",
journal = "Italian Heart Journal",
issn = "1129-471X",
publisher = "Societa Italiana di Cardiologia",
number = "5 Suppl",

}

TY - JOUR

T1 - Effetti cardiocircolatori dell'insulina nel paziente con insufficienza cardiaca.

AU - Tumminello, Gabriele

AU - Guazzi, Marco

PY - 2003/5

Y1 - 2003/5

N2 - Insulin is a hormone that possesses several therapeutic properties, some of which are only partially known and not definitely appreciated. Insulin appears to be an attractive therapeutic tool in several cardiovascular diseases and particularly in chronic heart failure (CHF). Insulin, in fact, exerts a direct effect on biological properties of myocytes by increasing the transmembrane glucose transport through glucose-specific insulin-regulated receptors, whose gene expression is down-regulated since the initial stages of myocyte hypertrophy. In addition, a hormonal antiapoptotic molecular effect has also been reported. These effects explain, at least in part, the observed improvement in ejection fraction and cardiac output in CHF patients when given insulin. Vasodilation is the most remarkable peripheral effect of insulin that seems to be due to a direct activity on vascular smooth muscle cells and, more remarkably, on an increased release of endothelium-derived relaxing factors, such as nitric oxide and vasodilator prostaglandins. In accordance with most recent clinical observations, this endothelial modulatory activity is not limited to the systemic circulation but involves also the pulmonary one and the alveolar-capillary interface, resulting in a facilitation of the alveolar gas diffusion. Such an effect on alveolar gas diffusion appears to play a major role in CHF patients. The present review focuses on the pathophysiological mechanisms underlying the insulin benefits, and emphasizes the hormone therapeutic applicability in a CHF setting.

AB - Insulin is a hormone that possesses several therapeutic properties, some of which are only partially known and not definitely appreciated. Insulin appears to be an attractive therapeutic tool in several cardiovascular diseases and particularly in chronic heart failure (CHF). Insulin, in fact, exerts a direct effect on biological properties of myocytes by increasing the transmembrane glucose transport through glucose-specific insulin-regulated receptors, whose gene expression is down-regulated since the initial stages of myocyte hypertrophy. In addition, a hormonal antiapoptotic molecular effect has also been reported. These effects explain, at least in part, the observed improvement in ejection fraction and cardiac output in CHF patients when given insulin. Vasodilation is the most remarkable peripheral effect of insulin that seems to be due to a direct activity on vascular smooth muscle cells and, more remarkably, on an increased release of endothelium-derived relaxing factors, such as nitric oxide and vasodilator prostaglandins. In accordance with most recent clinical observations, this endothelial modulatory activity is not limited to the systemic circulation but involves also the pulmonary one and the alveolar-capillary interface, resulting in a facilitation of the alveolar gas diffusion. Such an effect on alveolar gas diffusion appears to play a major role in CHF patients. The present review focuses on the pathophysiological mechanisms underlying the insulin benefits, and emphasizes the hormone therapeutic applicability in a CHF setting.

UR - http://www.scopus.com/inward/record.url?scp=0642336793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642336793&partnerID=8YFLogxK

M3 - Articolo

C2 - 12848074

VL - 4

SP - 368

EP - 374

JO - Italian Heart Journal

JF - Italian Heart Journal

SN - 1129-471X

IS - 5 Suppl

ER -